Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in
J

Josh WuUnclaimed

Guest on What's Next|科技早知道.

6PodCred credits

6 Feed-stated

Counts Verified and Feed-stated credits: what a show's own feed states, or a confirmation backs. See the record

  • Podcast guest

Claim this profile+ Add a creditIs this you? Claiming needs a free account. You sign in or join, then come straight back here.

This is not me · Request removal

+ FollowConnectMessageShare

This profile is unclaimed. PodSubs built it from public show feeds and credits. The person it is about has not reviewed it yet.

About this profile

Profile
Unclaimed
Guest appearances
6

People also viewed

  • A
    Aaron
  • A
    Afra(阿花)
  • A
    Alex
  • A
    Amber
  • A
    Amy Wu

As a guest

Josh Wu has been a guest on 6 episodes on What's Next|科技早知道, most recently in June 2024. That show covers technology.

Written by PodSubs from Josh's credits.

PodCred record

PodCred is the verified record of where Josh has worked and appeared. These credits come from the shows' own feeds and wait for people who were there to confirm them.

Worked with Josh on a show? This is where you give them credit.

+ Add a credit

Guest appearances

6 episodes

6 appearances
  • S8E08 | 药红是非多,从礼来新药获批看看千亿减肥药市场的竞争格局与新机会

    What's Next|科技早知道

    Jun 7, 202445 minAudio

    2023 年,让人「躺瘦」的 GLP-1 类产品司美格鲁肽无疑是减肥市场独一无二的明星。尤其是以减肥为适应症的产品 Wegovy,去年全球销量同比增长 407%, 甚至出现了供不应求,一药难求的情况。 药红是非多,司美格鲁肽的成功也带动了行业内的竞争。礼来的新药替尔泊肽也在今年 5 月 21 日在中国获批了糖尿病适应症。同时,国内多家制药公司也正准备将 GLP-1 类药物推向市场,也上演了一系列的专利之争。...

    Feed-stated
  • S7E25 | 一款意外发现的减肥「神药」,正在横扫全球

    What's Next|科技早知道

    Aug 22, 202345 minAudio

    节目赞助 本期节目由专业生发品牌【达霏欣】赞助播出,米诺地尔认准达霏欣。 达霏欣有 2%和5%两种浓度,低敏、副作用低,专业生发清爽不油腻。2%适合女性、敏感人群和轻度脱发人群,5%适合男性和中重度脱发人群。米诺地尔是中美食药监双认证的专业生发成分,也是三甲医院皮肤科用药。3个月一疗程,坚持使用一疗程即可看到绒毛生长。...

    Feed-stated
  • S7E13|这个六一,我们想聊硅谷大佬换血返童靠不靠谱

    What's Next|科技早知道

    May 31, 20231 hrAudio

    硅谷又有抗衰的新故事了,这一次是换血。 Bryan Johnson 在开启「蓝图计划」(Blueprint)并成功减龄五岁之后,开始尝试一种硅谷人不陌生的抗衰新策略 - 换血,而且是他的父亲与他的儿子共同参与,三代换血,力求实现可以让全人类可以受益的超长寿计划。但细究衰老的本质,换血真能让人类在这个时刻实现超越极限的寿命吗? 在去年科普过辉瑞小分子口服药之后,Josh再度做客「科技早知道」,与主播丁教探讨抗衰老的趣谈 -...

    Feed-stated
  • S5E33|新冠口服药的面世,究竟改变了什么?

    What's Next|科技早知道

    Nov 24, 202139 minAudio

    根据世界卫生组织的数据,截至北京时间 11 月 23 日,全球累计新冠肺炎确诊病例 2.57 亿例,累计死亡病例 515 万例,其中以欧洲及美国的情况最为严峻。为了应对随时可能再次爆发的第四轮疫情,英国在 11 月 4 日批准了默克口服药的紧急使用授权,拜登政府也在 11 月 16 日与辉瑞签订了新冠口服药 Paxlovid 的疗程购买协议。 与此同时,两家公司还与联合国支持的“药品专利储备”机构( MPP...

    Feed-stated
  • S5E20|打了疫苗我们还用担心 Delta 吗?

    What's Next|科技早知道

    Aug 11, 202140 minAudio

    Delta 毒株来势汹汹,打过疫苗还需要补打吗? 近期,传染性极强的 Delta 毒株又引起了新一轮的新冠病毒感染,英国等大范围接种了疫苗的国家仍然爆发了 Delta 疫情。 现有疫苗对 Delta 毒株防护效果如何?最好的疫苗接种策略是什么?打过灭活疫苗,还能打 mRNA 疫苗吗?疫苗的防护作用会随时间下降吗,是否需要定期补打? 本期节目,我们请到倍数资本合伙人 Josh Wu 返场,回答你最关心的疫苗问题。 ▼主播...

    Feed-stated
  • S5E14|精神疾病药物研发的新思路,投资大佬彼得·蒂尔支持的 ATAI 上市

    What's Next|科技早知道

    Jun 23, 202157 minAudio

    致幻药(psychedelic-drug)为何又受到资本热捧? 就在不久前的 6 月 17 日,专注于研发治疗精神疾病致幻药的 ATAI 生物科技公司上市,估值 22 亿美元,其创立至今才两年时间。而在 2020 年,同类公司 MindMed 和 Compass Pathways 早已相继上市。...

    Feed-stated
1 to 5 of 6

Guest record

Bookings completed
0
Verified appearances only
Host ratings
0
New guest. No ratings yet.

Availability

Availability not set yet.

Book this guestOne-sheet

Is an appearance missing?

People get invited back because someone remembered they were great. If you heard this person on a show and it is not listed here, add it. Your memory might be the reason they get their next invitation.

No account needed. Anyone can give a credit.

Add an appearanceHow PodCred works

Experience, education, skills, and recommendations start empty. They fill in when Josh claims this profile.

Recommendations

ReceivedGiven

No recommendations for Josh yet.

Recommendations open once Josh claims the profile.

Posts

No posts yet. Posts Josh shares on PodSubs, and what Josh publishes on Substack, YouTube and elsewhere, will show here.

Report this profile